Combination of Fibrinogen and High-sensitivity C-reactive Protein Measurements is Potential in Identification of Acute Coronary Syndrome

Djanggan Sargowo; Ferry Sandra

doi:10.18585/inabj.v7i1.19

Combination of Fibrinogen and High-sensitivity C-reactive Protein Measurements is Potential in Identification of Acute Coronary Syndrome

Djanggan Sargowo, Ferry Sandra

Abstract

BACKGROUND: Acute myocardial infarction (AMI) is one of cardiovascular diseases with high morbidity and mortality rates. Novel biomarkers that can detect accurately acute coronary syndrome (ACS) at early stage, are necessary to improve current strategies and/or to identify subjects who are at risk. Fibrinogen and high-sensitivity C-reactive protein (hs-CRP) roles in inflammation process could be potential for ACS early detection. This study was conducted to evaluate measurements of fibrinogen and hs-CRP on ACS.

METHODS: An analytic observational study with cross sectional approach was conducted on patients with Troponin I positive. After signing informed consent, anamnesis and complete blood count were conducted. Besides that, liver function, renal function, and blood glucose tests were conducted as well. Samples of selected subjects were quantified with enzyme-linked immunosorbent assay (ELISA) for Troponin I, fibrinogen and hs-CRP. Then statistical analyses were performed.

RESULTS: There were 76 subjects in each ACS and non-ACS groups. ACS group showed significant higher levels of both fibrinogen and hs-CRP compared to Non-ACS group (p=0.000). Among evaluated risk factors, diabetes mellitus (DM) (p=0.003) and hypertension (p=0.000) were significantly higher in ACS group than in non-ACS group. Among evaluated clinical factors, blood glucose (p=0.001) and age (p=0.000) were significantly higher in ACS group than in non-ACS group. Combination of fibrinogen and hs-CRP measurements showed the highest sensitivity (75.00%), specificity (80.26%), accuracy (77.63%), positive predictive value (79.19%) and negative predictive value (76.25%).

CONCLUSION: Since fibrinogen and hs-CRP were increased in ACS group and combination of fibrinogen and hs-CRP measurements showed the highest sensitivity, specificity, accuracy, positive predictive value and negative predictive value, we suggest that combination of fibrinogen and hs-CRP measurements could give added value to identify ACS.

KEYWORDS: fibrinogen, hs-CRP, biomarker, ACS, acute coronary syndrome, atherosclerosis, inflammation

Full Text:

PDF

References

Budiarso LR, Sarimawan. Survey Kesehatan Rumah Tangga (SKRT) Tahun 1992. Jakarta: Badan Penelitian dan Pengambangan Kesehatan Departemen Kesehatan RI; 1992.

Schulman SP, Fessler HE. Management of acute coronary syndromes. Am J Respir Crit Care Med. 2001; 164: 917-22, CrossRef.

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inlammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107: 499-511, CrossRef.

Acevedo M, Pearce GL, Kottke-Marchant K, Sprecher DL. Elevated fibrinogen and homocysteine levels enchance the risk of mortality in patient from a high-risk preventive cardiology clinic. Arterioscler Thromb Vasc Biol. 2002; 22: 1042-5, CrossRef.

Bucova M, Bernadic M, Buckingham T. C-reactive protein, cytokines and inlammation in cardiovascular disease. Bratisl Lek Listy. 2008; 109: 333-40, PMID.

Ben Khalfallah A, Sanaa I, Annabi N, Ousji M, Aloui H, Naffeti S. Predictive value of the markers of inlammation in acute coronary syndromes. Arch Mal Coeur Vaiss. 2005; 98: 899-905, PMID.

Virani SS, Polsani VR, Nambi V. Novel markers of inlammation in atherosclerosis. Curr Atheroscler Rep. 2008; 10: 164-70, CrossRef.

Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 1995; 15: 1263-8, CrossRef.

Haidari M, Javadi E, Sadeghi B, Hajilooi M, Ghanbili J. Evaluation of C-reactive protein, a sensitive marker of inlammation, as a risk factor for stable coronary artery diseases. Clin Biochem. 2001; 34: 309-15, CrossRef.

Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J. 2000; 140: 206-11, CrossRef.

Lauer MS. Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk. JAMA. 2007; 297: 1376-8, CrossRef.

Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inlammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000; 343: 1139-47, CrossRef.

Patel VB, Robbins MA, Topol EJ. C-reactive protein: a ‘golden marker’ for inlammation and coronary artery disease. Cleve Clin J Med. 2001; 68: 521-524, 521-34, CrossRef.

Littrell KA, Kern KB. Acute ischemic syndromes. Adjunctive therapy. Cardiol Clin. 2002; 20: 159-75, CrossRef.

Nordestgaard BG, Adourian AS, Freiberg JJ, Guo Y, Muntendam P, Falk E. Risk factors for near-term myocardial infarction in apparently healthy men and women. Clinical Chem. 2010; 56: 559-67, CrossRef.

Habib SS, Kurdi MI, Al Aseri Z, Suriya MO. CRP levels are higher in patients with ST elevation than non-ST elevation acute coronary syndrome. Arq Bras Cardiol. 2011; 96: 13-7, CrossRef.

Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inlammation in the prediction of cardiovascular disease in woman. N Eng J Med. 2000; 342: 836-43, CrossRef.

Pepys MB. C-reactive protein is neither a marker nor a mediator of atherosclerosis. Nat Clin Pract Nephrol. 2008; 4: 234-5, CrossRef.

Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inlammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation. 2004; 110: 1747-53, CrossRef.

Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med. 2006; 355: 2615-7, CrossRef.

Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008; 118: 2243-51, CrossRef.

DOI: https://doi.org/10.18585/inabj.v7i1.19

Copyright (c) 2015 The Prodia Education and Research Institute